Open Label, Randomized Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Two Doses of an Octreotide Implant in Patients With Carcinoid Syndrome.
Phase of Trial: Phase I/II
Latest Information Update: 19 Sep 2013
At a glance
- Drugs Octreotide (Primary)
- Indications Malignant carcinoid syndrome
- Focus Therapeutic Use
- 16 Aug 2012 Actual end date Dec 2011 added as reported by ClinicalTrials.gov.
- 16 Aug 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 22 Jul 2011 Planned End Date changed from 1 Feb 2011 to 1 Nov 2011 as reported by ClinicalTrials.gov.